[Cutaneous side effects of clinically relevant cytokine therapies].
Trefzer
U
U
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Charité, Humboldt-Universität zu Berlin.
Hofmann
M
M
Sterry
W
W
D000505:Alopecia / Q000139:chemically induced; D016207:Cytokines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003873:Dermatitis, Exfoliative / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology*; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000627:therapeutic use; D014657:Vasculitis / Q000139:chemically induced; D014820:Vitiligo / Q000139:chemically induced
D016207:Cytokines; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007372:Interferons